• Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growth
• RUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023
• Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 
• First nine months total revenues increased by 25% to US$204.5 million, compared to the first nine months 2023 
• On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)
• Third quarter operating profit increased to US$4.1 million from US$1.9 million in the third quarter 2023
• Overall cash and marketable securities increased to US$173.3 million at the end of the third quarter 2024 from US$161.8 million at the end of the second quarter 2024
• Sijmen de Vries, our Executive Director/Chief Executive Officer, has informed the Board of Directors that he will not be available for reappointment at the next Annual General Meeting of Shareholders in May 2025
• Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view webcast or register for the conference call)

Read full press release below